基本信息
浏览量:709
职业迁徙
个人简介
Dr. Chen’s lifetime research unveiled the cause-and-effect relationship between viral hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), particularly in chronic hepatitis B (CHB). His important and insightful discovery and perspective eventually led to a global campaign for universal hepatitis B virus (HBV) vaccination, which has saved millions of lives across the world.
In addition to HBV, Dr. Chen had a wide interest in many aspects of viral hepatitis. Hepatitis C virus (HCV), the etiologic agent of non-A, non-B hepatitis, was first identified in 1989. In Taiwan, chronic hepatitis C (CHC) was primarily transmitted by blood transfusion and was ranked as the second most common etiology for HCC. However, no effective antiviral treatment was available in the early 1990s. In 1991, Dr. Chen and his colleague, Dr. Ming-Yang Lai, pioneered a clinical trial to demonstrate the superiority of the combination therapy using interferon (IFN) plus ribavirin in comparison with IFN alone. This novel combinatorial antiviral regimen and later pegylated IFN plus ribavirin soon became the standard of care for CHC until the emergence of direct-acting antiviral agents. In addition, Dr. Chen also cooperated with Dr. Jin-Chuan Sheu to use ultrasonography for diagnosis of small HCC, demonstrating its ability for early detection of HCC. Routine ultrasonographic examination for HCC is now an effective measure to improve diagnosis and clinical outcomes. Moreover, Dr. Chen and Dr. Jin-Town Wang discovered GB virus-C (also named hepatitis G virus [HGV]) in a longitudinal post-transfusion hepatitis cohort and proved that GBV-C did not cause hepatitis.
In addition to HBV, Dr. Chen had a wide interest in many aspects of viral hepatitis. Hepatitis C virus (HCV), the etiologic agent of non-A, non-B hepatitis, was first identified in 1989. In Taiwan, chronic hepatitis C (CHC) was primarily transmitted by blood transfusion and was ranked as the second most common etiology for HCC. However, no effective antiviral treatment was available in the early 1990s. In 1991, Dr. Chen and his colleague, Dr. Ming-Yang Lai, pioneered a clinical trial to demonstrate the superiority of the combination therapy using interferon (IFN) plus ribavirin in comparison with IFN alone. This novel combinatorial antiviral regimen and later pegylated IFN plus ribavirin soon became the standard of care for CHC until the emergence of direct-acting antiviral agents. In addition, Dr. Chen also cooperated with Dr. Jin-Chuan Sheu to use ultrasonography for diagnosis of small HCC, demonstrating its ability for early detection of HCC. Routine ultrasonographic examination for HCC is now an effective measure to improve diagnosis and clinical outcomes. Moreover, Dr. Chen and Dr. Jin-Town Wang discovered GB virus-C (also named hepatitis G virus [HGV]) in a longitudinal post-transfusion hepatitis cohort and proved that GBV-C did not cause hepatitis.
研究兴趣
论文共 747 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ding‐Shinn Chen, Muyi Chou
Innovation in the Social Sciencesno. 1 (2023): 5-43
Yung-Tsung Li,Chun-Jen Liu,Jia-Horng Kao, Li-Feng Lin, Hui-Chu Tu,Chih-Chiang Wang, Po-Hsi Huang,Huei-Ru Cheng,Pei-Jer Chen,Ding-Shinn Chen,Hui-Lin Wu
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn